Rita Morigi, Chiara Zalambani, Giovanna Farruggia, Laura Verardi, Daniele Esposito, Alberto Leoni, Francesca Borsetti, Manuela Voltattorni, Laura Zambonin, Luca Pincigher, Natalia Calonghi, Alessandra Locatelli
In an initial screening, a series of novel Knoevenagel adducts were submitted to the National Cancer Institute for evaluation of antitumor activity in human cell lines. In particular, compound 5f showed remarkable selectivity against IGROV1, an ovarian cancer cell line, without affecting healthy human fibroblast cells. Analyses of cytotoxicity, cell proliferation, cell migration, epigenetic changes, gene expression, and DNA damage were performed to obtain detailed information about its antitumor properties...
April 2, 2024: European Journal of Medicinal Chemistry